ArticleProtein science : a publication of the Protein Society2026
AI-assisted design of a VEGFR2 agonistic peptide that promotes angiogenesis and wound repair.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-assisted design of a VEGFR2 agonistic peptide that promotes angiogenesis and wound repair.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Vascular endothelial growth factor (VEGF) serves as a principal regulator of neovascularization and is essential for vascular regeneration. In this study, we identified and evaluated VEGF Mimetic Peptide3 (VMP3), a novel synthetic peptide developed as a potential VEGFR-2/VEGF-A modulator. VMP3 was generated using an AI-assisted peptide design framework incorporating long short-term memory (LSTM) networks, which enabled learning of sequence-level patterns within known VEGF agonist peptides and assisted the motif-guided and structure-informed design of new candidates. Molecular dynamics simulations suggested a stable interaction profile between VMP3 and VEGFR2, supporting the feasibility of receptor engagement. Experimental validation was performed using in vitro, ex vivo, and in vivo methods. In vitro functional assays showed that VMP3 promoted endothelial cell proliferation, migration, and invasion in a manner similar to that of native VEGF. Ex vivo aortic ring assays supported these findings, demonstrating micro vessel sprouting following VMP3 treatment. An in vivo Matrigel plug assay in C57BL/6J mice revealed increased neovascularization following VMP3 treatment, as confirmed by histological and immunohistochemical analyses (H&E and CD31 staining). In addition, in a diabetic mouse wound healing model, VMP3 significantly accelerated wound closure, and tissue-level analysis of wound sites confirmed enhanced re-epithelialization and neovascularization, as evidenced by Masson's trichrome, Picrosirius Red, H&E, and CD31 staining. Collectively, these results suggested that VMP3 functions in a manner similar to that of VEGF, promoting angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.